Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-24), the Trailing Annual Dividend Yield of Karyopharm Therapeutics is 0.00%.
The historical rank and industry rank for Karyopharm Therapeutics's Dividend Yield % or its related term are showing as below:
STU:25K0's Dividend Yield % is not ranked *
in the Biotechnology industry.
Industry Median: 1.32 * Ranked among companies with meaningful Dividend Yield % only.
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:25K0 vs CHRS, TARA, CNTN: Dividend Yield % Comparison
For the Biotechnology subindustry, Karyopharm Therapeutics's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Karyopharm Therapeutics Dividend Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Karyopharm Therapeutics's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Karyopharm Therapeutics's Dividend Yield % falls into.
Karyopharm Therapeutics (STU:25K0) has a Dividend Yield % of 0.00% as of Jul. 24, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Karyopharm Therapeutics and its competitors. According to the industry distribution chart, Karyopharm Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry.
Is Karyopharm Therapeutics' Dividend Yield % too high?
Karyopharm Therapeutics' current Dividend Yield % is 0.00%. Based on the distribution chart, Karyopharm Therapeutics ranks #999999 out of 151 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Karyopharm Therapeutics has a GF Score™ of 60/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Karyopharm Therapeutics' Dividend Yield % compare to CHRS and TARA?
According to the Biotechnology industry distribution chart, Karyopharm Therapeutics ranks #999999 out of 151 companies for Dividend Yield %. This places Karyopharm Therapeutics in the lower half of its industry. The industry median Dividend Yield % is 1.32. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Biotechnology company?
The median Dividend Yield % among Biotechnology companies is 1.32, based on 151 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Karyopharm Therapeutics and its competitors. For the Biotechnology industry, the median Dividend Yield % is 1.32 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Karyopharm Therapeutics's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Karyopharm Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Karyopharm Therapeutics (STU:25K0) is currently considered Modestly Overvalued. The stock's GF Value™ is €5.22, compared to a current price of €6.15 — trading 17.8% above its estimated fair value. The current Dividend Yield % is 0.00%. Karyopharm Therapeutics' overall GF Score™ is 60/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Karyopharm Therapeutics (STU:25K0), the current Dividend Yield % is 0.00% as of Jul. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Karyopharm Therapeutics (STU:25K0) Overvalued in 2026?
Based on GuruFocus' analysis, Karyopharm Therapeutics stock appears to be overvalued.
The current stock price of €6.15 is trading 17.8% above its estimated GF Value™ of €5.22.
GuruFocus considers Karyopharm Therapeutics to be Modestly Overvalued.
Key valuation signals for STU:25K0:
Dividend Yield %: 0.00%
GF Value™: €5.22 vs. price of €6.15 (17.8% above fair value)
No single metric tells the full story. See the STU:25K0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company focused on novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. The company conducts research focused on intracellular communication between the nucleus and cytoplasm and has developed small-molecule compounds that inhibit exportin 1 (XPO1), a nuclear export protein. It is focused on marketing XPOVIO (selinexor).
60GF Score
Get the complete analysis for STU:25K0
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:25K0 has been successfully added to your 
